English press releases

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

– Phase 2b Trial Demonstrated Statistically Significant and Clinically Meaningful Improvements Across Primary and all Secondary Endpoints up to 8 Weeks – TAK-861 is the...

Unipart Logistics Selects Shippeo to Enhance Real-Time Visibility and Build Resilience and Sustainability for its Lead Logistics Partner Capability

Implementing Shippeo’s advanced high-quality data and real-time transportation visibility, Unipart Logistics enriches its Lead Logistics Partner (LLP) capability, equipping customers with heightened visibility, intelligence, and...

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in Patients with Newly...

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 If Approved in...

Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress

BAAR, Switzerland–(BUSINESS WIRE)– Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), hosted today a company-sponsored symposium entitled “Allergen harmony”: New data...

IFF Appoints Margarita Paláu-Hernández to Board of Directors

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) today announced the appointment of Margarita Paláu-Hernández to its Board of Directors, effective June 3, 2024. Paláu-Hernández joins as...

Phenom Named Strategic Leader in Fosway 9-Grid™ for Talent Acquisition 2024 for Fourth Consecutive Year

Latest Positioning Represents Intelligent Talent Experience Platform’s Ongoing Success Meeting the Complex TA Requirements of Europe’s Largest Companies LONDON–(BUSINESS WIRE)– Phenom has been named a...

Sunway Group Selects Rimini Street’s Software Support and Managed Services to Fund and Staff AI and CX Projects

With significant cost savings and optimization of IT resources, Malaysian conglomerate reallocates people, time and money towards digital transformation initiatives LAS VEGAS–(BUSINESS WIRE)– Rimini Street,...

H.I.G. WhiteHorse Europe Refinances Astek

LONDON–(BUSINESS WIRE)– H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital (“H.I.G.”), is pleased to announce that it has co-arranged a new...

Danone Joins 100+ Accelerator as Fifth Partner for Scaling Sustainable Startup Innovation

Danone joins AB InBev, The Coca-Cola Company, Colgate-Palmolive Company & Unilever to launch Cohort 6 of the 100+ Accelerator, combining efforts to develop and scale...

JEOL : – A Useful Tool for Every User! – New Electron Microscope JEM-120i Released

TOKYO–(BUSINESS WIRE)– JEOL Ltd. (TOKYO:6951)(President and CEO: Izumi Oi) announces the release of the new electron microscope JEM-120i developed with the concepts of “Compact”, “Easy...

IFF Details Sustainability Leadership in 2023 Do More Good Report

Last year, more than 90% of all new IFF innovations included a sustainability value proposition that supports people and the planet. NEW YORK–(BUSINESS WIRE)– IFF...

Sonar Delivers Clean Code Solution SonarQube Through Google Cloud Marketplace

Google Cloud Marketplace listing simplifies procurement, implementation, and management for efficient Clean Code delivery GENEVA & AUSTIN, Texas–(BUSINESS WIRE)– Sonar, the leader in Clean Code...

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

Data from various subgroup analyses of the CLEAR Outcomes trial of bempedoic acid, marketed as NILEMDO®▼ (bempedoic acid) and NUSTENDI®▼ (bempedoic acid / ezetimibe fixed-dose...

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

The WIN-B is a Phase Ib/II investigator-sponsored trial (IST) that will evaluate the safety and preliminary efficacy of the Debiopharm’s potent Wee-1 inhibitor Debio 0123...